Close Menu

NEW YORK (GenomeWeb) – Sequenta said this week that biopharmaceutical firm Celgene and others have made an equity investment into the company. Sequenta told GenomeWeb Daily News that the investment is a Series D financing but declined to disclose the amount or identify the other investors. The funding will support incorporation of Sequenta's ClonoSight test into clinical trials of medicines in development for blood cancers. It also will go toward development of new clinical diagnostics based on the company's LymphoSight platform.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

GenomeWeb reports that Veritas Genetics is suspending its US operations.

A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.

Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.

In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.